Form 4: Sangamo Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, sold shares to cover tax obligations related to vested restricted stock units.
Summary
- On January 22, 2025, Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, sold 129,593 shares of common stock at $1.15 per share to cover tax obligations.
- The sale was related to the vesting of a portion of a restricted stock unit (RSU) grant.
- Following the transaction, Dubois-Stringfellow beneficially owns 716,710 shares of Sangamo Therapeutics.
- These shares include those from previous RSU grants that are vesting in installments through January 22, 2026, and February 24, 2026, as well as shares acquired through the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so it doesn't significantly impact sentiment. It's a neutral event.
Future Outlook
The reporting person's remaining RSU grants will continue to vest in installments through January 22, 2026, and February 24, 2026, subject to continuous service.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders trade their company's stock. This provides transparency to the market.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading activities.
- Similar filings are common across the biotechnology industry, with executives often selling shares to cover tax obligations related to equity compensation.
- Companies like CRISPR Therapeutics and Editas Medicine also see regular Form 4 filings from their executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor, temporary impact on the stock price, but it's primarily driven by tax obligations and not a reflection of the executive's view of the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| February 25, 2022 | Date of RSU grant that will vest in one final installment on February 25, 2025. |
| February 24, 2023 | Date of RSU grant that will vest in successive equal quarterly installments through February 24, 2026. |
| January 22, 2024 | Date of RSU grant that will vest in successive equal quarterly installments through January 22, 2026. |
| November 29, 2024 | Date of acquisition of 5,000 shares under the Issuer's 2020 Employee Stock Purchase Plan. |
| January 22, 2025 | Date of transaction: Sale of shares to cover tax obligations related to RSU vesting. |
| January 24, 2025 | Date of signature of the Form 4 filing. |
| February 25, 2025 | Final vesting installment of February 25, 2022 RSU grant. |
| January 22, 2026 | Final vesting installment of January 22, 2024 RSU grant. |
| February 24, 2026 | Final vesting installment of February 24, 2023 RSU grant. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.